Entrada Therapeutics Inc (TRDA) AI Stock Analysis

• Market Cap: $262.26M
• Dividend Yield: N/A
• Average Volume (3M): 139.27K
• Price to Earnings (P/E): 8.5
• Beta (1Y): 1.58
• Revenue Growth: 5.74%
• EPS Growth: 24.45%
• Country: US
• Employees: 183
• Sector: Healthcare
• Sector Strength: 42
• Industry: Biotechnology
• EPS (TTM): -0.42
• Shares Outstanding: 37,953,420
• 10 Day Avg. Volume: 160,604
• 30 Day Avg. Volume: 139,267
• PEG Ratio: -0.12
• Price to Book (P/B): 1.79
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -9.64
• Enterprise Value/Market Cap: 2.79
• Enterprise Value/Revenue: 0.87
• Enterprise Value/Gross Profit: 4.32
• Enterprise Value/Ebitda: 3.49
• 1Y Price Target: $20.50
• Price Target Upside: 196.67% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 61 Neutral
• Price Target: $8.50 ▲(23.01%Upside)

The overall stock score for TRDA is driven by a strong valuation and positive corporate events. However, financial performance concerns, particularly recent declines in revenue and negative cash flows, combined with bearish technical signals, weigh on the stock's outlook.

Positive Factors

Gene Therapy Safety Concerns

Recent emergence of safety concerns with gene therapy for DMD may make Entrada's approach all the more relevant.

Product Pipeline Expansion

The company plans to submit global regulatory applications for ENTR-601-50 and ENTR-601-51, indicating a proactive approach in expanding its product offerings.

Regulatory Approvals

Entrada Therapeutics received authorization from the Health Authorities and Ethics Committees of multiple countries under the European Union Clinical Trial Regulation to initiate a Phase 1/2 clinical study for ENTR-601-45.

Negative Factors

Clinical Data Risks

Risks include failure to generate favorable mid-stage clinical data, inability to advance lead candidates into pivotal trials in a timely manner, negative data from pivotal studies, partnership risks, and long-term dilution risk.

Regulatory Challenges

In December 2022, the FDA issued a clinical hold in reference to the IND submission.

Entrada Therapeutics Inc Business Overview & Revenue Model

Company Description

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

How the Company Makes Money

Entrada Therapeutics generates revenue through strategic collaborations and partnerships with other pharmaceutical and biotechnology companies. These partnerships often involve licensing their proprietary EEV technology for the development of therapies targeting specific diseases, leading to potential milestone payments and royalties based on the success of the partnered products. Additionally, Entrada may earn revenue from government grants or research funding to support its innovative therapeutic projects. As the company advances its own pipeline of investigational drugs, future revenue could also come from the commercialization of its proprietary therapeutics, contingent upon successful clinical trials and regulatory approval.

Entrada Therapeutics Inc Financial Statement Overview

Summary

Entrada Therapeutics Inc. has demonstrated impressive past revenue growth with a positive net income in 2024, reflecting effective profitability improvements. However, recent declines in revenue and net income, along with negative cash flow, highlight challenges in sustaining growth and financial stability. The balance sheet is strong with low leverage, but cash flow volatility and reliance on external funding are concerns.

Income Statement

Entrada Therapeutics Inc. has demonstrated significant revenue growth over recent years, with a notable increase in total revenue from $0 in 2021 to $210.78 million in 2024. The company achieved a positive net income of $65.63 million in 2024, indicating improving profitability. However, the TTM data shows a decline in revenue to $172.22 million and net income to $24.78 million, suggesting recent challenges. Gross profit margins have been strong, and the EBIT and EBITDA margins indicate operational efficiency improvements. Despite these, the recent dip in revenue and earnings raises concerns about sustaining growth momentum.

Balance Sheet

The balance sheet reveals a solid equity position with a stockholders' equity of $417.26 million in the latest TTM. The debt-to-equity ratio remains low, indicating prudent financial leverage. The company's total assets have grown significantly, and cash reserves are robust, reflecting strong liquidity. However, the stability of equity amidst fluctuating liabilities warrants attention. Overall, the balance sheet showcases financial stability, though vigilance is needed to maintain a low leverage profile.

Cash Flow

Cash flow analysis shows a volatile operating cash flow, with the latest TTM indicating a negative figure of $-54.55 million. Free cash flow has also been negative, reflecting high capital expenditures relative to cash generated from operations. The substantial financing cash flow suggests reliance on external funding to support operations. While capital investments are necessary for growth, the persistent cash outflows pose a risk if not offset by future revenue increases.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	172.22M	210.78M	129.01M	0.00	0.00	0.00
Gross Profit	169.43M	207.01M	29.13M	-1.90M	-1.12M	-326.00K
EBITDA	6.05M	47.01M	-321.00K	-95.35M	-50.01M	-26.34M
Net Income	24.78M	65.63M	-6.68M	-87.46M	-50.07M	-26.38M
Balance Sheet
Total Assets	486.48M	526.32M	469.19M	252.06M	305.83M	43.53M
Cash, Cash Equivalents and Short-Term Investments	382.51M	420.00M	351.97M	45.16M	291.06M	39.05M
Total Debt	57.00M	59.21M	68.23M	25.94M	0.00	0.00
Total Liabilities	69.22M	97.64M	226.83M	39.50M	7.12M	85.02M
Stockholders Equity	417.26M	428.68M	242.36M	212.55M	298.72M	-41.49M
Cash Flow
Free Cash Flow	-58.01M	-44.72M	134.19M	-96.67M	-55.44M	-27.89M
Operating Cash Flow	-54.55M	-41.56M	139.80M	-93.79M	-50.86M	-25.57M
Investing Cash Flow	-49.16M	-27.80M	-138.40M	-148.65M	-4.58M	-2.32M
Financing Cash Flow	103.11M	102.96M	21.04M	479.00K	307.46M	50.09M

Entrada Therapeutics Inc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 6.91
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TRDA, the sentiment is Negative. The current price of 6.91 is below the 20-day moving average (MA) of 7.60, below the 50-day MA of 8.06, and below the 200-day MA of 13.12, indicating a bearish trend. The MACD of -0.34 indicates Positive momentum. The RSI at 33.55 is Neutral, neither overbought nor oversold. The STOCH value of 15.19 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TRDA.

Entrada Therapeutics Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RIGL	74 Outperform	$348.15M	9.40	531.78%	―	68.74%	―
TRDA	61 Neutral	$262.26M	8.55	7.22%	―	5.74%	24.45%
AMLX	58 Neutral	$564.26M	―	-83.24%	―	-100.32%	-197.69%
Sector *	51 Neutral	$7.41B	0.36	-61.88%	2.33%	17.09%	1.64%
ALLO	43 Neutral	$258.10M	―	-59.60%	―	-100.00%	31.43%
ZBIO	42 Neutral	$400.77M	―	-115.47%	―	―	―
BNTC	38 Underperform	$297.94M	―	-48.57%	―	-100.00%	83.98%

Entrada Therapeutics Inc Corporate Events

Entrada Therapeutics Holds Virtual Annual Stockholders Meeting

On June 11, 2025, Entrada Therapeutics, Inc. held its Annual Meeting of Stockholders virtually, where a quorum was established with 30,259,526 shares represented. During the meeting, stockholders elected three Class I directors to the Board and ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (TRDA) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Entrada Therapeutics Inc stock, see the TRDA Stock Forecast page.

Entrada Therapeutics Appoints New Board Member

On May 30, 2025, Entrada Therapeutics expanded its Board of Directors from six to seven members, appointing Maha Radhakrishnan, M.D., as a Class III director and a member of the Audit Committee, effective June 1, 2025. Dr. Radhakrishnan brings extensive experience in global drug development, which is expected to support Entrada’s clinical momentum, particularly in advancing its Duchenne muscular dystrophy programs. Her appointment is seen as a strategic move to enhance the company’s capability in delivering innovative therapies for serious illnesses.

The most recent analyst rating on (TRDA) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Entrada Therapeutics Inc stock, see the TRDA Stock Forecast page.